| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de2076d9a31cb72c082bf1aec6a0ce30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2007-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07c6b1f5d432e5aea061241d1f7aa88c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24a04ed151e65e7b2a049c96a9ceb8df |
| publicationDate |
2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-017265-B1 |
| titleOfInvention |
APPLICATION OF IMC-A12 ANTIBODY, WHICH IS IGF-IR INHIBITOR, FOR THE TREATMENT OF PROSTATE CANCER |
| abstract |
The invention relates to a method for the treatment of prostate cancer using therapy with androgen deprivation and an insulin-like growth factor receptor antagonist (IGF-IR). Although the response of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells inevitably become androgen-independent (AI) and tumor growth continues. The invention inhibits or delays the transition from androgen-dependent cancer to androgen-independent cancer, significantly reducing the risk of recurrence and improving the outcome of treatment. |
| priorityDate |
2006-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |